ribavirin + placebo

This is a combination of ribavirin, an antiviral nucleoside analogue, and placebo. Ribavirin is primarily used in combination with other antiviral agents (such as interferon alfa or peginterferon alfa) for the treatment of chronic hepatitis C virus infection. It acts by interfering with viral RNA synthesis and increasing mutation frequency in viral genomes, thereby inhibiting replication of both RNA and DNA viruses. Placebo is an inert substance with no pharmacological activity, included here as a control agent in clinical trials to assess the efficacy and safety of ribavirin[1][3][5][7]. This combination does not represent a therapeutic regimen but rather a study design element where patients may receive either active drug (ribavirin) or placebo.